1. Radiation proctitis after iodine-125 low-dose-rate prostate brachytherapy utilizing SpaceOAR hydrogel.
- Author
-
Morita M, Hiramatsu A, Nishimura K, Yanagida W, Nakamura S, Yamatoya J, Noguchi T, Tanabe M, Fukagai T, and Lederer JL
- Subjects
- Humans, Male, Retrospective Studies, Aged, Middle Aged, Hydrogels, Incidence, Colonoscopy adverse effects, Colonoscopy methods, Radiotherapy Dosage, Aged, 80 and over, Argon Plasma Coagulation methods, Argon Plasma Coagulation adverse effects, Brachytherapy adverse effects, Brachytherapy methods, Prostatic Neoplasms radiotherapy, Proctitis etiology, Proctitis diagnosis, Radiation Injuries etiology, Radiation Injuries epidemiology, Radiation Injuries diagnosis, Iodine Radioisotopes adverse effects, Iodine Radioisotopes administration & dosage, Iodine Radioisotopes therapeutic use
- Abstract
Objective: We retrospectively evaluated the efficacy of combining the SpaceOAR (SOAR) hydrogel with prostate brachytherapy, using colonoscopy findings to assess for radiation proctitis., Methods: Among 731 patients undergoing iodine-125 low-dose-rate prostate brachytherapy (LDR-BT), SOAR was utilized in 394 patients (53.9%). Colonoscopy was performed for 97 patients (13.3%) to assess the presence, location, condition, and treatment of radiation proctitis. We also investigated treatment factors associated with the occurrence of radiation proctitis., Results: Radiation proctitis was observed in 57 patients (7.8%) and 17 (2.3%) were treated with argon plasma coagulation (APC). The incidence of radiation proctitis was 12.2% in the non-SOAR and 4.1% in the SOAR group (p < 0.001). In the non-SOAR group, the incidence of radiation proctitis was 6.6% for LDR-BT monotherapy and increased to 22.0% when combined with external beam radiation therapy (EBRT) (p = 0.001). However, in the SOAR group, these rates significantly decreased to 3.3% and 5.7% for monotherapy and combination therapy, respectively (p = 0.035, p < 0.001). With SOAR, inflammation was observed directly above the DL in most patients (87.5%), and only one patient (6.3%) required APC. The absence of SOAR (p < 0.001, HR = 0.29) and the concurrent use of EBRT (p = 0.018, HR = 2.87) were identified as significant risk factors for the occurrence of radiation proctitis., Conclusion: The use of SOAR significantly reduced the incidence of radiation proctitis in patients undergoing LDR-BT monotherapy and combined EBRT. Inflammation primarily occurred directly above the DL; further examination is necessary to clarify its cause., (© 2024 The Japanese Urological Association.)
- Published
- 2024
- Full Text
- View/download PDF